| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
OGG1 ( IC50 = 0.059 μM )
SU-0268 targets 8-oxoguanine DNA glycosylase 1 (OGG1), a DNA repair enzyme involved in the base excision repair pathway that removes oxidized guanine bases (8-oxoguanine) from DNA. SU-0268 inhibits OGG1 with an IC50 of 0.059 µM. At 20 µM, it is selective for OGG1 over other DNA repair enzymes, including MTH1, dUTPase, NUDT16, ABH2, ABH3, and SMUG1. |
|---|---|
| ln Vitro |
IACS-4759 and SU0268 co-treated cells (5–20 μM, 48 hours) outperformed IACS treated in the same way [1]. More viable cells are those treated with SU0268 or -4759 [1]. reacts to OGG1 oscillations rather than its substrate since it does not bind DNA [2]. SU0268 reduces obesity and stops the course of disease by inducing the release of type I interferons along the DNA-cGAS-STING-IRF3-IFN-β axis [3].
In vitro, SU-0268 potently inhibits OGG1 with an IC50 of 0.059 µM. At 0.5 µM, it inhibits OGG1 activity and increases the number of 8-oxoguanine DNA lesions in HeLa cell lysates. The compound regulates inflammatory responses during Pseudomonas aeruginosa infection. SU-0268 is a specific inhibitor of OGG1 and is selective over a panel of related DNA repair enzymes. |
| ln Vivo |
SU0268 grooming (10 mg/kg, intranasal therapy) enhanced the mortality of MH-S cells and C57BL/6N mice compared with pregnancies without SU0268 grooming [3].
In vivo activity data for SU-0268 are not extensively detailed in the available sources. The compound regulates inflammatory responses during Pseudomonas aeruginosa infection, suggesting potential in vivo activity in infectious disease models. OGG1 inhibitors such as SU-0268 are being investigated as promising targets in cancer therapy due to the involvement of DNA glycosylases in the DNA base excision repair pathway. |
| Enzyme Assay |
The in vitro enzyme assay for SU-0268 involves measuring the inhibition of OGG1 enzymatic activity. OGG1 is a DNA glycosylase that excises 8-oxoguanine from DNA. The assay typically uses a fluorescently labeled oligonucleotide substrate containing 8-oxoguanine. The enzyme's activity is measured by the release of the damaged base, and inhibition by SU-0268 is quantified to determine the IC50 value of 0.059 µM.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: A549 shGFP and shMTH1 (2000 cells per well). Tested Concentrations: 0.1μM, 0.5μM, 1μM, 2.5μM, 5μM, 7.5μM, 10μM. Incubation Duration: 24 or 48 hrs (hours). Experimental Results: shGFP cells were more susceptible to OGG1 inhibition by increasing SU0268 doses than shMTH1 cells, especially at the 48 time point. Cellular assays for SU-0268 are performed using HeLa cell lysates or other cell lines. Cells are treated with SU-0268 at various concentrations (e.g., 0.5 µM), and OGG1 activity is assessed by measuring the accumulation of 8-oxoguanine DNA lesions. The compound's ability to inhibit OGG1 in a cellular context is confirmed by quantifying DNA damage using techniques such as ELISA or comet assays. |
| Animal Protocol |
Animal/Disease Models: Anesthetize C57BL/ 6N mice [3].
Doses: 10 mg/kg. Route of Administration: Intranasal treatment. Experimental Results: Dramatically inhibited inflammatory response and alleviated Pseudomonas aeruginosa infection. In vivo animal studies for SU-0268 are not detailed in the available sources. The compound has been shown to regulate inflammatory responses during Pseudomonas aeruginosa infection, suggesting that it may have been evaluated in relevant animal models of bacterial infection. OGG1 inhibitors are also being explored in cancer therapy, though specific in vivo efficacy data for SU-0268 have not been reported. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for SU-0268 are not available in the provided sources. The compound has a molecular weight of 475.56 g/mol and a molecular formula of C26H25N3O4S. It is soluble in DMF (10 mg/mL), DMSO (10 mg/mL), and ethanol (15 mg/mL), but is insoluble in PBS (pH 7.2). The compound should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for SU-0268 are not reported in the available sources. As a research compound, it is not intended for therapeutic use. The compound is supplied as a research tool for studying OGG1 function in DNA repair and inflammation. Specific toxicological profiles have not been characterized in the supplier documentation.
|
| References |
|
| Additional Infomation |
SU-0268 is a research compound for studying OGG1 function in DNA repair, inflammation, and cancer. It is a potent and specific OGG1 inhibitor with an IC50 of 0.059 µM. The compound is available from commercial suppliers for research use only and is not approved for human therapeutic use. DNA glycosylases involved in the base excision repair pathway are promising targets in cancer therapy.
|
| Molecular Formula |
C26H25N3O4S
|
|---|---|
| Molecular Weight |
475.5594
|
| Exact Mass |
475.16
|
| Elemental Analysis |
C, 65.67; H, 5.30; N, 8.84; O, 13.46; S, 6.74
|
| CAS # |
2210228-45-6
|
| PubChem CID |
154934526
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
860
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2=C(C=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=CC(=CC=C4)C(=O)N)N(C1)C(=O)C5CC5
|
| InChi Key |
XGGNCZLDTJOSFV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H25N3O4S/c27-25(30)21-4-1-3-20(15-21)17-9-12-23(13-10-17)34(32,33)28-22-11-8-18-5-2-14-29(24(18)16-22)26(31)19-6-7-19/h1,3-4,8-13,15-16,19,28H,2,5-7,14H2,(H2,27,30)
|
| Chemical Name |
3-[4-[[1-(cyclopropanecarbonyl)-3,4-dihydro-2H-quinolin-7-yl]sulfamoyl]phenyl]benzamide
|
| Synonyms |
SU0268; SU-0268; SU 0268
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 95~100 mg/mL (199.8~210.3 mM)
Ethanol: 2 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1028 mL | 10.5139 mL | 21.0278 mL | |
| 5 mM | 0.4206 mL | 2.1028 mL | 4.2056 mL | |
| 10 mM | 0.2103 mL | 1.0514 mL | 2.1028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
